In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria

Koji Takemoto,Ryo Nakayama,Koichi Fujimoto,Yumiko Suzuki,Yukiko Takarabe,Masako Honsho,Sachiko Kitahara,Yoshihiko Noguchi,Hidehito Matsui,Tomoyasu Hirose,Yukihiro Asami,Jun Hidaka,Toshiaki Sunazuka,Hideaki Hanaki

DOI: https://doi.org/10.1128/aac.01602-23

IF: 5.938

2024-05-07

Antimicrobial Agents and Chemotherapy

Abstract:ABSTRACT KSP-1007 is a novel bicyclic boronate-based broad-spectrum β-lactamase inhibitor and is being developed in combination with meropenem (MEM) for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria, a global health concern, and here, we describe its characteristics. KSP-1007 exhibited low apparent inhibition constant ( K i app ) values against all classes of β-lactamase, including imipenemase types and oxacillinase types from Acinetobacter baumannii . Against 207 Enterobacterales and 55 A . baumannii , including carbapenemase producers, KSP-1007 at fixed concentrations of 4, 8, and 16 μg/mL dose-dependently potentiated the in vitro activity of MEM in broth microdilution MIC testing. The MIC 90 of MEM/KSP-1007 at 8 μg/mL against Enterobacterales was lower than those of MEM/vaborbactam, ceftazidime/avibactam, imipenem/relebactam, and colistin and similar to those of aztreonam/avibactam, cefiderocol, and tigecycline. The in vitro activity of MEM/KSP-1007 at ≥4 μg/mL against Enterobacterales harboring metallo-β-lactamase was superior to that of cefepime/taniborbactam. MEM/KSP-1007 showed excellent activity against Escherichia coli with PBP3 mutations and New Delhi metallo-β-lactamase compared to aztreonam/avibactam, cefepime/taniborbactam, and cefiderocol. MEM/KSP-1007 at 8 μg/mL showed greater efficacy against A. baumannii than these comparators except for cefiderocol, tigecycline, and colistin. A 2-fold reduction in MEM MIC against 96 Pseudomonas aeruginosa was observed in combination with KSP-1007. MEM/KSP-1007 demonstrated bactericidal activity against carbapenemase-producing Enterobacterales , A. baumannii , and P. aeruginosa based on minimum bactericidal concentration/MIC ratios of ≤4. KSP-1007 enhanced the in vivo activity of MEM against carbapenemase-producing Enterobacterales , A. baumannii , and P. aeruginosa in murine systemic, complicated urinary tract, and thigh infection models. Collectively, MEM/KSP-1007 has a good profile for treating carbapenem-resistant Gram-negative bacterial infections.

pharmacology & pharmacy,microbiology

What problem does this paper attempt to address?

The paper focuses on addressing the issue of antibiotic resistance in Gram-negative bacteria, particularly those resistant to carbapenems, which is a significant global health concern. The authors present KSP-1007, a novel broad-spectrum β-lactamase inhibitor, and investigate its effectiveness when combined with meropenem (MEM) against carbapenem-resistant Gram-negative bacteria. Key points addressed in the paper include: 1. **Overview of the Problem**: Carbapenem-resistant Gram-negative bacteria (CR-GNB), including carbapenem-resistant *Enterobacterales* (CRE), *Acinetobacter baumannii* (CRAB), and *Pseudomonas aeruginosa* (CRPA), pose a major threat to public health due to limited treatment options. 2. **Current Treatments and Their Limitations**: Polymyxins and aminoglycosides are used but have limitations like nephrotoxicity and increasing resistance. Tetracyclines like tigecycline have poor lung and urinary tract exposure. 3. **Development of KSP-1007**: The authors introduce KSP-1007, a novel boronic acid-based β-lactamase inhibitor designed to overcome resistance by inhibiting both serine- and metallo-β-lactamases. It is being developed in combination with meropenem. 4. **In Vitro and In Vivo Activities**: The paper describes the in vitro and in vivo activities of KSP-1007 in combination with meropenem. It shows that KSP-1007 potentiates the activity of meropenem against a wide range of carbapenem-resistant and carbapenemase-producing isolates, including those pro

In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in an imipenem-resistant Serratia marcescens isolate

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant Klebsiella pneumoniae

In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates

Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model

In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem

In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China

Activities of aztreonam in combination with several novel β-lactam-β-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae strains coproducing KPC and NDM

In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens

Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis

Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae

Study of In Vitro Synergistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing Klebsiella pneumoniae .

Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment.

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime

Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae

Polymyxin B and Fosfomycin Thwart KPC-producing Klebsiella Pneumoniae in the Hollow-Fibre Infection Model

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae